Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12009459 | 0.78 | MAPT (0.34) | CRHR1TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL19366819 | 0.78 | KDM4E (0.30) | — | |
| SCHEMBL12795919 | 0.76 | CA1 (0.31) | CA1CA2 | |
| SCHEMBL26714411 | 0.74 | CA1 (0.30) | CA1CA2 | |
| SCHEMBL20354259 | 0.74 | ALDH1A1 (0.39) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL20844006 | 0.71 | POLB (0.35) | LMNA | |
| SCHEMBL20673422 | 0.71 | CRHR1 (0.33) | CRHR1 | |
| SCHEMBL26710206 | 0.71 | CRHR1 (0.30) | CRHR1 | |
| SCHEMBL26714412 | 0.70 | — | — | |
| SCHEMBL20280294 | 0.70 | CRHR1 (0.38) | CRHR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248968-A2 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20200369648-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-26 | — | — | US | disclosed |
| US-10836750-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-11-17 | — | — | US | disclosed |
| US-10793553-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| WO-2019018354-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | WO | disclosed |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369648-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CRHR1 1137/4885TRPA1 513/4885LMNA 1703/4885 |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CRHR1 1223/4885TRPA1 346/4885LMNA 1770/4885 |
| US-10793553-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | CRHR1 1223/4885TRPA1 346/4885LMNA 1770/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CRHR1 1223/4885TRPA1 346/4885LMNA 1770/4885 |
| US-10836750-B1 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | CRHR1 1137/4885TRPA1 513/4885LMNA 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.